Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab


Study First Submitted Date 2021-11-17
Study First Posted Date 2021-12-28
Last Update Posted Date 2022-04-28
Verification Month Year April 2022
Verification Date 2022-04-30
Last Update Posted Date 2022-04-28

Browse Interventions

Sequence: 95816021 Sequence: 95816022 Sequence: 95816023 Sequence: 95816024 Sequence: 95816025 Sequence: 95816026
Mesh Term Nivolumab Mesh Term Relatlimab Mesh Term Antineoplastic Agents, Immunological Mesh Term Antineoplastic Agents Mesh Term Immune Checkpoint Inhibitors Mesh Term Molecular Mechanisms of Pharmacological Action
Downcase Mesh Term nivolumab Downcase Mesh Term relatlimab Downcase Mesh Term antineoplastic agents, immunological Downcase Mesh Term antineoplastic agents Downcase Mesh Term immune checkpoint inhibitors Downcase Mesh Term molecular mechanisms of pharmacological action
Mesh Type mesh-list Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor

Id Information

Sequence: 40066482
Id Source org_study_id
Id Value CA224-129


Sequence: 42464486 Sequence: 42464487 Sequence: 42464488 Sequence: 42464489 Sequence: 42464490 Sequence: 42464491 Sequence: 42464492
Name Australia Name Brazil Name Israel Name Italy Name Singapore Name Switzerland Name United States
Removed True Removed True Removed True Removed True Removed True Removed True Removed True


Sequence: 52367026
Intervention Type Biological
Name Nivolumab plus Relatlimab FDC


Sequence: 48210834
Agency Class INDUSTRY
Lead Or Collaborator lead
Name Bristol-Myers Squibb

Overall Officials

Sequence: 29217282
Role Study Director
Name Bristol-Myers Squibb
Affiliation Bristol-Myers Squibb


Sequence: 30697158
Minimum Age N/A
Maximum Age N/A
Adult True
Child True
Older Adult True

Calculated Values

Sequence: 253910918
Registered In Calendar Year 2021
Were Results Reported False
Has Single Facility False


Sequence: 4377533 Sequence: 4377534 Sequence: 4377535 Sequence: 4377536
Url https://www.bms.com/healthcare-providers/early-patient-access-to-investigational-medicine/investigational-drugs-available.html Url https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html Url https://www.bmsstudyconnect.com/s/US/English/USenHome Url https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description Pre-approval Access (PAA) Healthcare Practitioner Requests Description BMS Clinical Trial Information Description BMS Clinical Trial Patient Recruiting Description FDA Safety Alerts and Recalls

Responsible Parties

Sequence: 28810328
Responsible Party Type Sponsor